1. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413–24.
2. Sjostrom J, Blomqvist C, Mouridsen H et al. Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group. Eur J Cancer 1999; 35: 1194–201.
3. Thomas E, Buzdar A, Theriault R et al. Role of paclitaxel in adjuvant therapy of operable breast cancer: preliminary results of a prospective randomized clinical trial [abstract]. Proc ASCO 2000; 19: 74a.
4. Mamounas EP. Evaluating the use of paclitaxel following doxorubicin/cyclophosphamide in patients with breast cancer and positive axillary node. Proceedings from the NIH Consensus Development Conference on Adjuvant Therapy for Breast Cancer; 2000 Nov 1–3, 2000; Bethesda. Bethesda (MD): National Institutes of Health; 2000.
5. Wolowacz SE, Cameron DA, Tate HC, Bagust AJ. Docetaxel in Combination With Doxorubicin and Cyclophosphamide As Adjuvant Treatment for Early Node-Positive Breast Cancer: A Cost-Effectiveness and Cost-Utility Analysis Clin Oncol 2008; 26: 925–33.
6. Jones SE, Savin MA, Holmes FA et al. Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer. J Clin Oncol Dec 2006; 24: 5381–7.
7. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812–23.
8. Marty M, Cognetti F, Maraninchi D et al. Superior long-term survival benefits of trastuzumab plus docetaxel compared to docetaxel alone in patients with HER2-positive metastatic breast cancer: Patients surviving more than 4 years in the M77001 study. Breast Cancer Res Treat 2006; 100 (suppl. 1): S103.
9. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–92.
10. Miller K, Wang M et al. Paclitaxel plus Bevacizumab versus Paclitaxel alone for Metastatic Breast cancer. N Engl J Med 2007; 357: 26.
11. Klencke BJ et al. Independent review of E 2100 progression free survival (PFS) with the addition of bevacizumab to paclitaxel as initial chemotherapy for metastatic breast cancer. J Clin Oncol 2008; 26 (May 20) suppl.: abstr 1036.
12. Wagner L, Wang M, Miller K et al. Health-related quality of life among patients with metastatic breast cancer receiving paclitaxel versus paclitaxel plus bevacizumab: results from the Eastern Cooperative Oncology Group (ECOG) study E2100. Breast Cancer Res Treat 2006; 100 (Suppl. 1): S239 (abstr).
13. Miles D, Chan A, Romieu G et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer: AVADO. ASCO 2008; abstr LBA 1011.
14. Fumoleau P, Greil R, Rayson D et al. Bevacizumab maintenance therapy significantly delays disease progression or death compared with placebo in the AVADO trial. SABCS 2008. post. 903.

Л.Г.Жукова

РОНЦ им. Н.Н.Блохина РАМН, Москва